Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

TELA TELA Bio Inc

Price (delayed)

$1.88

Market cap

$74.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.35

Enterprise value

$72.54M

TELA Bio Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is ...

Highlights
TELA Bio's EPS has increased by 19% YoY
TELA's revenue is up by 13% year-on-year and by 2.8% since the previous quarter
The equity has declined by 36% since the previous quarter but it has grown by 26% year-on-year
The quick ratio is down by 20% since the previous quarter but it is up by 3.8% year-on-year
The company's net income fell by 15% QoQ and by 8% YoY
The gross margin is down by 3% year-on-year

Key stats

What are the main financial stats of TELA
Market
Shares outstanding
39.55M
Market cap
$74.36M
Enterprise value
$72.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.1
Price to sales (P/S)
1.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.02
Earnings
Revenue
$71.22M
Gross profit
$47.66M
Operating income
-$39.76M
Net income
-$43.44M
EBIT
-$38.36M
EBITDA
-$37.31M
Free cash flow
-$37.65M
Per share
EPS
-$1.35
EPS diluted
-$1.35
Free cash flow per share
-$0.83
Book value per share
$0.46
Revenue per share
$1.57
TBVPS
$1.67
Balance sheet
Total assets
$77.25M
Total liabilities
$59.13M
Debt
$41.28M
Equity
$18.12M
Working capital
$53.21M
Liquidity
Debt to equity
2.28
Current ratio
4.22
Quick ratio
3.24
Net debt/EBITDA
0.05
Margins
EBITDA margin
-52.4%
Gross margin
66.9%
Net margin
-61%
Operating margin
-55.8%
Efficiency
Return on assets
-62.7%
Return on equity
-402.5%
Return on invested capital
-66.8%
Return on capital employed
-63.2%
Return on sales
-53.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TELA stock price

How has the TELA Bio stock price performed over time
Intraday
19.75%
1 week
35.25%
1 month
84.31%
1 year
-67.08%
YTD
-37.75%
QTD
54.1%

Financial performance

How have TELA Bio's revenue and profit performed over time
Revenue
$71.22M
Gross profit
$47.66M
Operating income
-$39.76M
Net income
-$43.44M
Gross margin
66.9%
Net margin
-61%
The operating margin has grown by 22% YoY and by 7% from the previous quarter
The company's net income fell by 15% QoQ and by 8% YoY
TELA's revenue is up by 13% year-on-year and by 2.8% since the previous quarter
TELA Bio's net margin has decreased by 12% from the previous quarter but it has increased by 4.4% YoY

Price vs fundamentals

How does TELA's price correlate with its fundamentals

Growth

What is TELA Bio's growth rate over time

Valuation

What is TELA Bio stock price valuation
P/E
N/A
P/B
4.1
P/S
1.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.02
TELA Bio's EPS has increased by 19% YoY
The P/B is 66% less than the 5-year quarterly average of 12.2
The equity has declined by 36% since the previous quarter but it has grown by 26% year-on-year
TELA's price to sales (P/S) is 78% less than its 5-year quarterly average of 5.3
TELA's revenue is up by 13% year-on-year and by 2.8% since the previous quarter

Efficiency

How efficient is TELA Bio business performance
TELA Bio's return on equity has shrunk by 159% YoY and by 4.9% QoQ
TELA's ROA is down by 29% year-on-year and by 13% since the previous quarter
TELA's ROIC is down by 18% QoQ and by 3.2% YoY
TELA Bio's ROS has decreased by 14% from the previous quarter but it has increased by 2.7% YoY

Dividends

What is TELA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TELA.

Financial health

How did TELA Bio financials performed over time
TELA's total assets is 31% more than its total liabilities
The quick ratio is down by 20% since the previous quarter but it is up by 3.8% year-on-year
The current ratio has contracted by 16% from the previous quarter but it has grown by 2.2% YoY
TELA Bio's debt is 128% more than its equity
TELA Bio's debt to equity has surged by 57% QoQ but it has decreased by 19% YoY
The equity has declined by 36% since the previous quarter but it has grown by 26% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.